FDA Investigator

Massoud Motamed, FDA Investigator

Also appears on FDA documents as Motamed, Massoud, M. Motamed.

Human DrugsBiologicsFoods & CosmeticsAnimal Drugs & Feeds

FDA inspection record · Last updated August 15, 2026

Overview

  • 62 inspections across 59 sites are on record.
  • 245 Form 483 observations are attributed to this investigator.
  • Most recent recorded activity is 2026-02-17.

About Massoud Motamed

Massoud Motamed is an FDA investigator with 62 inspections at 59 sites and 245 Form 483 observations on record since April 2015, most recently in Livingston, United Kingdom in February 2026. The published record holds 24 of the resulting Form 483s, issued between April 2015 and June 2017.

Those 24 forms are long: 9.1 observations on average, against an industry median of three. The longest, 36 observations, went to Allergan Sales in Waco, Texas in October 2016. Others include Mylan Pharmaceuticals in Morgantown (10), I.V. Specialty in Austin (18), Talon Compounding Pharmacy in San Antonio (13) and Temmentech in Switzerland (12). Foreign inspections include Fresenius Kabi Austria in Graz, ILS in Derby, UK, and three Indian facilities: Mylan Laboratories in Nashik, QbD Research in Thane and Doctors' Analytical Laboratories in Navi Mumbai.

Sterile and compounding operations are a recurring thread, with US Compounding in Conway inspected twice and Cantrell Drug Company in Little Rock. The section cited most is 21 CFR 211.192, investigations of discrepancies and failures, on seven of the 12 forms with structured citations, followed by 211.113(b) aseptic process validation and the 211.42(c)(10) aseptic area requirements. For what a 483 is and what follows one, see what an FDA Form 483 is.

At a glance

Inspections

62

Sites

59

Observations

245

Career since

Apr 2015

Form 483s on record

Every Form 483 in the published record that names Massoud Motamed, most recent first.

IssuedCompany and facilityCategoryObservations
29 Jun 2017Cantrell Drug CompanyLittle Rock, United StatesHuman Drugs8
17 Mar 2017Fresenius Kabi AustriaGraz, AustriaHuman Drugs6
7 Mar 2017ILS LimitedDerby, United KingdomHuman Drugs4
12 Jan 2017FUJIFILM Ultra Pure Solutions, IncCarrollton, United StatesHuman Drugs4
18 Nov 2016Mylan Pharmaceuticals IncMorgantown, United StatesHuman Drugs10
28 Oct 2016Allergan Sales, LLCWaco, United StatesHuman Drugs36
14 Sep 2016Mylan Laboratories LimitedNasik, Nashik, IndiaHuman Drugs6
15 Jul 2016US Compounding IncConway, United StatesHuman Drugs6
17 Jun 2016Temmentech AGSumiswald, SwitzerlandHuman Drugs12
16 Mar 2016Wellmark International dba Central Life SciencesDallas, United StatesAnimal Drugs & Feeds4
29 Feb 2016QbD Research and Development Lab Pvt. Ltd.Thane, IndiaHuman Drugs9
24 Feb 2016Doctors' Analytical Laboratories Private LimitedNavi Mumbai, IndiaHuman Drugs6
5 Feb 2016I.V. Specialty, LtdAustin, United StatesHuman Drugs18
20 Nov 2015Nippon Sanso Matheson, Inc.Dallas, United StatesHuman Drugs4
17 Nov 2015Mary Kay, IncDallas, United StatesHuman Drugs10
22 Oct 2015L & M Pharmaceuticals, Inc.Redfield, United StatesAnimal Drugs & Feeds10
21 Oct 2015Tribute LabsConway, United StatesHuman Drugs7
8 Oct 2015Goodier Cosmetics LLCDallas, United StatesHuman Drugs10
21 Aug 2015US Compounding IncConway, United StatesHuman Drugs10
24 Jun 2015Talon Compounding PharmacySan Antonio, United StatesHuman Drugs13
10 Jun 2015Blount Fine Foods, Inc.Mckinney, United StatesFoods & Cosmetics8
3 Jun 2015America's Beverage CompanyIrving, United StatesFoods & Cosmetics2
10 Apr 2015Target DC T3897Denton, United StatesFoods & Cosmetics5
1 Apr 2015B & P Industrial Inc.Tulsa, United StatesHuman Drugs10

Regulations cited most

How many of Massoud Motamed's Form 483s cite each section of the Code of Federal Regulations.

RegulationWhat it coversForm 483s citing it
21 CFR 211.192Production record review and investigation of discrepancies7
21 CFR 211.113(b)Control of microbiological contamination4
21 CFR 211.160(b)Laboratory controls, general requirements3
21 CFR 211.42(c)(10)(iv)Design and construction of facilities, including aseptic processing areas3
21 CFR 211.165(e)Testing and release for distribution2
21 CFR 211.22(a)Responsibilities of the quality control unit2
21 CFR 211.110(a)Sampling and testing of in-process materials2
21 CFR 211.42(c)(10)(vi)Design and construction of facilities, including aseptic processing areas2

Recent inspections

Most recent inspections in the published record.

SiteDateCategoryForm 483
Valneva Scotland Ltd.17 Feb 2026BiologicsOn file
Serum Institute of India Private Ltd.30 Jan 2026BiologicsOn file
Genzyme Ireland Limited20 Jan 2026BiologicsOn file
Genzyme Flanders7 Nov 2025BiologicsOn file
Celgene Corporation18 Jul 2025BiologicsOn file

Sites inspected

Valneva Scotland Ltd.Livingston, United Kingdom1 insp.
Genzyme Ireland LimitedWaterford, Ireland1 insp.
Genzyme FlandersGeel, Belgium1 insp.
Celgene CorporationSummit, United States1 insp.

Co-investigators

Investigators who co-signed a Form 483 with Massoud Motamed.

Full investigator report

Get the verbatim findings behind Massoud Motamed's 245 observations

Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.

  • New inspections and Form 483s, mapped to the CFR citation
  • Warning letter outcomes, and the citation patterns they repeat
  • Their co-investigators, so no surprises about who shows up on site

FAQ

Questions about FDA investigator Massoud Motamed

Answers drawn from Massoud Motamed's inspection and Form 483 record.

Who is Massoud Motamed at the FDA?

Massoud Motamed is an FDA investigator with 62 inspections at 59 sites since April 2015 and 245 Form 483 observations on record. The published Form 483s cover drug manufacturers, compounding pharmacies and food facilities in Texas, Arkansas and Oklahoma, plus inspections in India, Austria, Switzerland and the United Kingdom, where the most recent inspection on record took place in February 2026.

How many Form 483s has Massoud Motamed issued?

The published record holds 24 Form 483s that name Massoud Motamed, issued between April 2015 and June 2017. They average 9.1 observations, three times the 2025 median of three, and the longest, to Allergan Sales in Waco, Texas in October 2016, carried 36. Each form is listed in the table above.

What does Massoud Motamed cite most on Form 483s?

21 CFR 211.192, investigation of discrepancies and failures, appears on seven of the 12 Massoud Motamed Form 483s with structured citations. 21 CFR 211.113(b), validation of aseptic processes, follows on four, and the aseptic area requirements under 211.42(c)(10) on three, reflecting the sterile and compounding facilities in the record.

Which companies has Massoud Motamed inspected?

Companies with a Form 483 from Massoud Motamed include Mylan Pharmaceuticals in Morgantown, Mylan Laboratories in Nashik, Allergan Sales in Waco, Fresenius Kabi Austria in Graz, Temmentech in Switzerland, ILS in Derby, Mary Kay in Dallas and US Compounding in Conway, Arkansas. The full list is in the table above.

Who does Massoud Motamed inspect with?

Latorie S Jones, Scott T Ballard, Shelby N Marler, Matthew R Maddox and Karlton T Watson each co-signed two of the published Massoud Motamed Form 483s. The co-investigator list above links to each profile on record.